The effect of selective PPAR-alpha modulator to Non alcoholic fatty liver disease with dyslipidemia.

The effect of selective PPAR-alpha modulator to Non alcoholic fatty liver disease with dyslipidemia. - The effect of selective PPAR-alpha modulator to Non alcoholic fatty liver disease with dyslipidemia.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000037615

Enrollment

Registered

2019-10-01

Start date

2019-09-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non alcoholic fatty liver disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients with NAFLD shown ALT>31 U/L and TG>150mg/dL

Exclusion criteria

Exclusion criteria: patients with cirrhosis patients with gallstones patients administered fibrate

Design outcomes

Primary

Measure	Time frame
The change in ALT at 12 weeks after medication	—

Countries

Japan

Contacts

Public ContactYuya Seko

Kyoto Prefectural University of Medicine Department of Molecular Gastroenterology and Hepatology

yuyaseko@koto.kpu-m.ac.jp0752515519

Outcome results